|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019169,
umls-concept:C0019682,
umls-concept:C0026882,
umls-concept:C0030705,
umls-concept:C0035379,
umls-concept:C0151317,
umls-concept:C0205195,
umls-concept:C0209738,
umls-concept:C0332154,
umls-concept:C0332173,
umls-concept:C0332307,
umls-concept:C0439210,
umls-concept:C0540694,
umls-concept:C0683598
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-4-17
|
|
pubmed:abstractText |
Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-10612317,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-10612325,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-10815085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-10869300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-11397660,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-11551579,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-2847636,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-7486942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-8878611,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-8891152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-9237705,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-9395363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-9660994,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11959607-9828233
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1586-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11959607-Adenine,
pubmed-meshheading:11959607-Antiviral Agents,
pubmed-meshheading:11959607-Drug Resistance, Viral,
pubmed-meshheading:11959607-Drug Therapy, Combination,
pubmed-meshheading:11959607-HIV Infections,
pubmed-meshheading:11959607-HIV Reverse Transcriptase,
pubmed-meshheading:11959607-HIV-1,
pubmed-meshheading:11959607-Hepatitis B, Chronic,
pubmed-meshheading:11959607-Hepatitis B virus,
pubmed-meshheading:11959607-Humans,
pubmed-meshheading:11959607-Lamivudine,
pubmed-meshheading:11959607-Mutation,
pubmed-meshheading:11959607-Phosphonic Acids,
pubmed-meshheading:11959607-Reverse Transcriptase Inhibitors
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
|
|
pubmed:affiliation |
Department of Virology, Pitié-Salpêtrière Hospital, Paris, France.
|
|
pubmed:publicationType |
Journal Article
|
